Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Ziconotide for Refractory Pain
NCT01992562Phase 4Withdrawn
- Sponsor
- The Boster Center for Multiple Sclerosis
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of ziconotide in myelopathy, peripheral neuropathy, sponsored by The Boster Center for Multiple Sclerosis. Planned start Jan 2014; status: withdrawn.
02
Drugs
ziconotide
03
Conditions
myelopathyperipheral neuropathy
Beyond the preview
Go deeper on NCT01992562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01992562.